🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

FDA turmoil is creating huge uncertainty for biotech... so much institutional knowledge is being lost... and upheaval is never good for productivity. One of the most challenging aspects of this uncertainty is it's not clear (at least to me) what the direction of travel will be

Counting your blessings is good for happiness. Counting your contributions is better for motivation.

Our next guest (Ep.16) on BioVenture VoiCes will be Josh Resnick MD, Partner at RA Capital Management and President of Raven, RA's Venture strategy. He describes his journey from his MD/MBA at UPenn to his experience as a practicing clinician and creating companies / VC investing at

𝐇𝐒𝐁𝐂 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐁𝐚𝐧𝐤𝐢𝐧𝐠: HSBC's Jonathan Norris shares an update on Q1 venture numbers for healthcare, and how the venture side of the sector is holding up in these volatile times. Read his full-year 2024 report: business.us.hsbc.com/en/campaigns/i… #sponsored

Listen to Episode 16 of BioVentureVoiCes video podcast w/ Josh Resnick MD of RA Capital Management and President of Raven (RA Ventures) and hear about how he merged interests in science and business as an MD/MBA at multiple VCs with company creation before joining RA, while maintaining a

Biotech Venture Creation: The Benefits Of Scarcity. The equity markets have collapsed in 2025, the IPO window is closed, the FDA is in turmoil, the NIH is being gutted… and it’s a great time to start new biotech companies. lifescivc.com/2025/04/biotec…

How do you raise capital in times of extreme disruption, volatility, and uncertainty? A few suggestions for those who are out marketing right now. 1) First, determine whether you need to tweak your financing plan / messaging. If you are going out for a seed or Series A and you’re

𝐓𝐨𝐦𝐨𝐫𝐫𝐨𝐰: Tune in tomorrow for a new episode of Off-Target Effects with Matt Gline. Matt interviews Avoro Capital's Behzad Aghazadeh.

I was asked, “how bad is the market now compared to prior downturns?” While it’s easy to check on how public indices are doing, it’s harder to gauge real-time impact on the private market. Reports on VC activity are put out periodically by HSBC, SVB, and others – but those will

Listen to Episode 17 of BioVentureVoiCes video podcast w/ Tiba Aynechi of Norwest and hear about how she is applying her biophysics/computational drug discovery training and her ~20 years of deal making/VC investing, including 12 yrs at Novo Holdings / Novo Ventures, to

When deciding which team members to bring to a pitch, consider who will do the talking. Many times the presentation is done by only one or two people, and others are present simply to answer questions. This may not be the most efficient use of your team’s time, especially for a

There's lots of noise about how the changes at the FDA are having a negative impact on biotech as a sector. FDA departures must be bad for business. Drug delays make sensational headlines. But I don't think the sky is falling at the FDA, or at least not yet. I do expect that

Cantor has put out some really interesting notes lately. Dueling takes from Eric Schmidt & Josh Schimmer on short selling last week and then this week a thoughtful critique of issues that are ailing our industry. Link below: cantor2.bluematrix.com/sellside/Email…

Listen to Episode 18 of BioVentureVoiCes video podcast w/ Jory Bell of Playground Global and hear about how he is applying Playground's Deep Tech expertise to engineered biology and life sciences investing, along with his early career designing laptop computers at Apple and as an

Dads are spending 3-4x as much time with their kids as their dads did with them. When father figures are engaged, kids show better cognitive development, boys have fewer behavioral problems, and girls have fewer emotional problems. Every child deserves strong parental bonds.

Listen to Episode 21 of BioVentureVoiCes video podcast w/ Aaron Kantoff of Scion Life Sciences and hear about his early influences to pursue biotech VC and his successful partnership with his Scion co-founder Sam Hall at Apple Tree Partners. Aaron has been involved in a number

URGENT call to action: please contact any Republican senator you know to keep ORPHAN Cures Act & Accelerating Access for Kids Act in the reconciliation bill - at high risk of being removed Biotechnology Innovation Organization #BIO2025

We’re in an incredibly challenging time for biotech fundraising. Endpoints reported on July 3 that megarounds ($100M+) were down 38% in 1H25 vs. the year prior, and that Q2’25 was tracking to be the slowest quarter for private biotech fundraising in over seven years. This also

Big late stage win for Takeda! Oveporexton (TAK-861) hits on all endpoints in narcolepsy for the first-in-class orexin receptor 2 selective agonist. Congrats to Andy Plump and the team at $TAK - perseverance and conviction on the MoA paid off takeda.com/newsroom/newsr…

In this challenging fundraising market, some companies are taking the somewhat unusual tactic of connecting interested firms with one another ahead of a term sheet. This approach has its pros and cons but is worth exploring in a market like the current one, characterized by a